Scarica l'app Stockscreener
1.03
8.67%
0.0822
Dopo l'orario di chiusura:
1.03
Precedente Chiudi:
$0.9478
Aprire:
$0.95
Volume 24 ore:
2.48M
Relative Volume:
1.78
Capitalizzazione di mercato:
$260.49M
Reddito:
$14.78M
Utile/perdita netta:
$-64.01M
Rapporto P/E:
-3.5851
EPS:
-0.2873
Flusso di cassa netto:
$-22.59M
1 W Prestazione:
+0.00%
1M Prestazione:
-8.85%
6M Prestazione:
-33.55%
1 anno Prestazione:
-33.55%
Intervallo 1D:
$0.9419
$1.04
Intervallo di 1 settimana:
$0.9101
$1.05
Portata 52W:
$0.9101
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Nome
Lineage Cell Therapeutics Inc
Settore
Industria
Telefono
510-871-4188
Indirizzo
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.03 | 260.49M | 14.78M | -64.01M | -22.59M | -0.2873 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-20 | Iniziato | Craig Hallum | Buy |
| 2022-11-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-14 | Iniziato | B. Riley Securities | Buy |
| 2021-08-19 | Iniziato | Noble Capital Markets | Outperform |
| 2021-03-31 | Iniziato | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Borsa (LCTX) Ultime notizie
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform - BioSpace
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE 5D Manufacturing Platform - Investing News Network
LCTX Looks 6.9% Undervalued on GF Value™ as Stem Cell Patent Boo - GuruFocus
Lineage Cell Therapeutics Inc. (LCTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Lineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical Risk - Seeking Alpha
Lineage Cell Therapeutics Inc. (LCTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Lineage Cell Therapeutics Inc. (LCTX) Peer Comparison – Compare with Others - Value Research
Lineage (LCTX) Earnings Snapshot: The Bottom-Line Figure Trails Its Comparison at the Close; Post-Earnings: The Market Reaction Is Muted in the Latest ReadingLow Estimate Range - careplusvn.com
Lineage Cell Therapeutics Inc (NYSE: LCTX) Stock Price, News & Analysis - kalkine.ca
LCTX Q2 2026 Earnings: Wider-Than-Expected Loss Keeps Focus on Cell Therapy PipelineEPS Growth Rate - Vinanet
LCTX Q2 2026 Earnings: Slight EPS Miss Overshadowed as Shares Rise $0.94Revenue Surprise History - Vinanet
LCTX Q2 2026 Earnings: Modest EPS Miss Overshadowed by Clinical-Stage FocusOne-Time Loss Impact - Vinanet
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript - AOL.ca
Lineage Cell Therapeutics (LCTX) Falls 3.6% to $1.06 as Biotech Sentiment WeighsDealer Gamma - vinanet.vn
Lineage Cell Therapeutics Q3 EPS Reduced by HC Wainwright - MarketBeat
LCTX Q2 2026 Earnings: Wider-Than-Expected Loss Pressures SharesEPS Consistency Score - dars.gov.et
Lineage Cell Therapeutics (LCTX) Climbs 3.18% to $1.14 as Buyers Defend Key SupportArms Index - careplusvn.com
Lineage Cell Therapeutics Q2 Earnings Call Highlights - MarketBeat
CCORF Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Lineage Cell Therapeutics, Inc. (LCTX) stock price, news, quote and history - Yahoo Finance Australia
Lineage Cell Therapeutics Balances Progress and Risk - TipRanks
Lineage Cell Therapeutics (LCTX) Stock Faces Cash Burn Despite Paper Profit - simplywall.st
Lineage Cell Therapeutics Inc (LCTX) Stock News Today - TradingKey
Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - biospace.com
Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Hig - GuruFocus
LCTX Looks 13.7% Undervalued on GF Value™ - GuruFocus
Transcript : Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
Earnings call transcript: Lineage Cell Therapeutics posts Q2 2026 profit, extends runway - Investing.com
Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Lineage Cell: Q2 Earnings Snapshot - marketscreener.com
[10-Q] Lineage Cell Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Lineage Cell Therapeutics (LCTX) Holds Above $1.07 Support as Biotech ConsolidatesOpening Range Breakout - dars.gov.et
3 Penny Stocks With Market Caps Larger Than $40M To Watch - webull.com
Lineage Cell Therapeutics (LCTX) Nudges Higher, Consolidating Between $1.06 Support and $1.18 ResistanceAAII Bearish - dars.gov.et
Lineage Cell Therapeutics (LCTX) to Post Earnings on Thursday - MarketBeat
Lineage Cell Therapeutics, Inc. Revenue Breakdown – AMEX:LCTX - TradingView
Earnings Preview: LCTX to Report Financial Results Post-market on August 06 - Moomoo
Lineage Cell Therapeutics to announce Q2 2026 results on August 6 with business update call - Traders Union
Lineage Cell Therapeutics (LCTX) Holds Above $1.04 Support After 0.90% PullbackProfitability Factor - careplusvn.com
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 - Business Wire
BlackRock, Inc. (LCTX) discloses 5.3% beneficial ownership in Lineage Cell - Stock Titan
Lineage Cell Therapeutics Inc (LCTX) Income Statement - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Cash Flow - TradingKey
Lineage Cell Therapeutics Inc - TradingKey
LCTX|Lineage Cell Therapeutics Inc|Price:1.035|Chg%:+0.005 - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Balance Sheet - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lineage Cell Therapeutics Inc Azioni (LCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):